BN Business News
Add your company to Business Communicator →

Technology · 09/10/2026Updated: 10/17/2026 · 1 min read

European Medicines Agency Approves Modification to Paediatric Investigation Plan for Aimovig and Erenumab

The European Medicines Agency has issued an opinion and decision on a Paediatric Investigation Plan (PIP) for Aimovig and Erenumab, a therapeutic area of surgical and medical procedures, following a modification application to the agreed PIP.

Original source language: EMA — Paediatric Investigation PlansOpen original release →

Explore insights

Business insights →